Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan-based conditioning for UCBT in hematological malignancies
NCT00796068Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Feb 2009; status: completed.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00796068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796068.